Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | ACHE | P22303 | 2/20 | 0.37 |
| ▸ | RORC | P51449 | 3/20 | 0.36 |
| ▸ | KLK7 | P49862 | 4/20 | 0.35 |
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25339569 | 0.93 | KMT2A (0.40) | KMT2AL3MBTL1CA1CA2ACHE | |
| SCHEMBL30352483 | 0.85 | KMT2A (0.39) | KMT2AL3MBTL1CA1CA2ACHE | |
| SCHEMBL29626333 | 0.81 | KMT2A (0.36) | KMT2AL3MBTL1CA1CA2ACHE | |
| SCHEMBL29132503 | 0.81 | CA1 (0.43) | KMT2AL3MBTL1CA1CA2ACHE | |
| SCHEMBL29626234 | 0.81 | CA1 (0.43) | KMT2AL3MBTL1CA1CA2ACHE | |
| SCHEMBL29132491 | 0.80 | NFKB1 (0.38) | KMT2AL3MBTL1CA1CA2ACHE | |
| SCHEMBL30683975 | 0.80 | NFKB1 (0.38) | KMT2AL3MBTL1CA1CA2ACHE | |
| SCHEMBL29132483 | 0.80 | RORC (0.34) | KMT2AL3MBTL1CA1CA2ACHE | |
| SCHEMBL30683988 | 0.80 | RORC (0.34) | KMT2AL3MBTL1CA1CA2ACHE | |
| SCHEMBL25338361 | 0.78 | CA1 (0.44) | KMT2AL3MBTL1CA1CA2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122160-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | CALICO LIFE SCIENCES LLC (US) | 2025-04-17 | — | — | US | disclosed |
| EP-4211122-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | Calico Life Sciences LLC (US) | 2023-07-19 | — | — | EP | disclosed |
| WO-2022056281-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | CALICO LIFE SCIENCES LLC (US) | 2022-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122160-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PTPN1, PTPN2, PTPN18 | KMT2A 1767/4885L3MBTL1 3049/4885CA1 4547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.